Citations (27)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Andrés J. Muñoz, Laura Ortega, Ana Gutiérrez, Enrique Gallardo, Darío Rubio-Rodríguez, Carlos Rubio-Terrés, Blanca Morón, Pilar García-Alfonso & José Manuel Soria. (2023) Cost-effectiveness of apixaban and rivaroxaban in thromboprophylaxis of cancer patients treated with chemotherapy in Spain. Journal of Medical Economics 26:1, pages 1145-1154.
Read now
Read now
Nan Zhao, Qian Xiang, Zhiyan Liu, Xia Zhao & Yimin Cui. (2020) Pharmacokinetic-Pharmacodynamic Analysis’ Role in Design of Phase ⅠClinical Trials of Anticoagulant Agents: A Systematic Review. Expert Review of Clinical Pharmacology 13:11, pages 1191-1202.
Read now
Read now
Jennifer L Koehl, Bryan D. Hayes, Hanny Al‐Samkari & Rachel Rosovsky. (2020) A comprehensive evaluation of apixaban in the treatment of venous thromboembolism. Expert Review of Hematology 13:2, pages 155-173.
Read now
Read now
Vladimir Trkulja. (2016) Safety of apixaban for venous thromboembolism prophylaxis: the evidence to date. Drug, Healthcare and Patient Safety 8, pages 25-38.
Read now
Read now
Ymer H Mekaj, Agon Y Mekaj, Shkelzen B Duci & Ermira I Miftari. (2015) New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events. Therapeutics and Clinical Risk Management 11, pages 967-977.
Read now
Read now
Pontus B Persson. (2015) Pharmacodynamics and Pharmacokinetics of oral factor Xa inhibitors. Clinical Pharmacology: Advances and Applications 7, pages 77-78.
Read now
Read now
Articles from other publishers (21)
Mitsushige Sugimoto, Masaki Murata & Takashi Kawai. (2023) Assessment of delayed bleeding after endoscopic submucosal dissection of early-stage gastrointestinal tumors in patients receiving direct oral anticoagulants. World Journal of Gastroenterology 29:19, pages 2916-2931.
Crossref
Crossref
Azfar Zaman, Bernard Prendergast, David Hildick-Smith, Daniel Blackman, Richard Anderson, Mark S Spence, Darren Mylotte, David Smith, Ben Wilding, Chris Chapman, Kirsty Atkins, Kevin G Pollock, Ayesha C Qureshi & Adrian Banning. (2023) An Update on Anti-thrombotic Therapy Following Transcatheter Aortic Valve Implantation: Expert Cardiologist Opinion from a UK and Ireland Delphi Group. Interventional Cardiology: Reviews, Research, Resources 18.
Crossref
Crossref
Oluwadolapo D. LawalHerbert D. Aronow, Fisayomi ShobayoAnne L. HumeTracey H. TaveiraKelly L. MatsonYichi ZhangXuerong Wen. (2023) Comparative Effectiveness and Safety of Direct Oral Anticoagulants and Warfarin in Patients With Atrial Fibrillation and Chronic Liver Disease: A Nationwide Cohort Study. Circulation 147:10, pages 782-794.
Crossref
Crossref
Xiuehui Chen, Lili Wang, Huijun Li, Weichao Huang, Lingyue Zhao & Wenqin Guo. (2023) Comparative differences in the risk of major gastrointestinal bleeding among different direct oral anticoagulants: An updated traditional and Bayesian network meta-analysis. Frontiers in Pharmacology 13.
Crossref
Crossref
Arnar B. Ingason, Johann P. Hreinsson & Einar S. Björnsson. (2022) Gastrointestinal Bleeding on Oral Anticoagulation: What is Currently Known. Drug Safety 45:12, pages 1449-1456.
Crossref
Crossref
Ghadeer K. Dawwas, Adam Cuker, Geoffrey D. Barnes, James D. Lewis & Sean Hennessy. (2022) Apixaban Versus Rivaroxaban in Patients With Atrial Fibrillation and Valvular Heart Disease. Annals of Internal Medicine 175:11, pages 1506-1514.
Crossref
Crossref
Takako Terakami, Satomi Nagaya, Kenshi Hayashi, Hiroshi Furusho, Noboru Fujino, Takeshi Kato, Hidesaku Asakura & Eriko Morishita. (2022) Effect on Plasma Protein S Activity in Patients Receiving the Factor Xa Inhibitors. Journal of Atherosclerosis and Thrombosis 29:7, pages 1059-1068.
Crossref
Crossref
Se Min Ryu, Sung-Min Park, Se-Ran Yang, Seong-Joon Cho, Sook Won Ryu & Seung-Hwan Lee. (2022) Direct Oral Anticoagulants for Anticoagulation after Initial Management of Venous Thromboembolism. Annals of Phlebology 20:1, pages 9-14.
Crossref
Crossref
E. A. Shmidt, S. A. Berns, T. Yu. Penskaya, I. I. Zhidkova, O. V. Gruzdeva & O. L. Barbarash. (2022) Coagulation status in patients with pulmonary embolism receiving long-term anticoagulant therapy. Cardiovascular Therapy and Prevention 20:8, pages 3093.
Crossref
Crossref
Ghadeer K. Dawwas, Charles E. Leonard, James D. Lewis & Adam Cuker. (2022) Risk for Recurrent Venous Thromboembolism and Bleeding With Apixaban Compared With Rivaroxaban: An Analysis of Real-World Data. Annals of Internal Medicine 175:1, pages 20-28.
Crossref
Crossref
Arnar B. Ingason, Jóhann P. Hreinsson, Arnar S. Ágústsson, Sigrún H. Lund, Edward RumbaDaníel A. PálssonIndriði E. ReynissonBrynja R. GuðmundsdóttirPáll T. Önundarson & Einar S. Björnsson. (2021) Rivaroxaban Is Associated With Higher Rates of Gastrointestinal Bleeding Than Other Direct Oral Anticoagulants. Annals of Internal Medicine 174:11, pages 1493-1502.
Crossref
Crossref
Marina Yu. Maksimova, Andrei V. Fonyakin & Liudmila A. Geraskina. (2021) Prevention of ischemic stroke in atrial fibrillation from the point of view of a neurologist. Standards and real clinical practice. Terapevticheskii arkhiv 93:10, pages 1240-1245.
Crossref
Crossref
Gilda D. Zielinski, Nienke van Rein, Martina Teichert, Frederikus A. Klok, Frits R. Rosendaal, Felix J. M. van der Meer, Menno V. Huisman, Suzanne C. Cannegieter & Willem M. Lijfering. (2021) Adherence to direct oral anticoagulant treatment for atrial fibrillation in the Netherlands: A surveillance study. Pharmacoepidemiology and Drug Safety 30:8, pages 1027-1036.
Crossref
Crossref
Adela-Nicoleta Roşian, Ştefan Horia Roşian, Bela Kiss, Maria Georgia Ştefan, Adrian Pavel Trifa, Camelia Diana Ober, Ovidiu Anchidin & Anca Dana Buzoianu. (2020) Interindividual Variability of Apixaban Plasma Concentrations: Influence of Clinical and Genetic Factors in a Real-Life Cohort of Atrial Fibrillation Patients. Genes 11:4, pages 438.
Crossref
Crossref
T. V. Vavilova. (2019) Anticoagulant activity of direct factor Xa inhibitors as a tool to ensure the effectiveness and safety of drugs intake. Kardiologiia 59:11S, pages 28-35.
Crossref
Crossref
Fanny Ofek, Dana Barchel, Nofar Perets, Tomer Ziv-Baran, Ahmad Mahajna, Talia Filipovich-Rimon, Osnat Garach-Jehoshua, Maya Berlin & Matitiahu Berkovitch. (2019) International Normalized Ratio as a Screening Test for Assessment of Anticoagulant Activity for Patients Treated With Rivaroxaban or Apixaban: A Pilot Study. Frontiers in Pharmacology 10.
Crossref
Crossref
Jennifer Yee & Colin Kaide. (2019) Emergency Reversal of Anticoagulation. Western Journal of Emergency Medicine 20:5, pages 770-783.
Crossref
Crossref
Panayiotis K. Karampinas, Panayiotis D. Megaloikonomos, Kalliopi Lampropoulou-Adamidou, Eleftherios G. Papadelis, Andreas F. Mavrogenis, John A. Vlamis & Spyros G. Pneumaticos. (2018) Similar thromboprophylaxis with rivaroxaban and low molecular weight heparin but fewer hemorrhagic complications with combined intra-articular and intravenous tranexamic acid in total knee arthroplasty. European Journal of Orthopaedic Surgery & Traumatology 29:2, pages 455-460.
Crossref
Crossref
Jang Ho Lee, Dong-gon Hyun, Chang Min Choi, Jae Cheol Lee, Woo Sung Kim, Yeon-Mok Oh, Sang-Do Lee & Jae Seung Lee. (2019) A Retrospective Study on Efficacy and Safety of Rivaroxaban and Dalteparin for Long-Term Treatment of Venous Thromboembolism in Patients with Lung Cancer. Respiration 98:3, pages 203-211.
Crossref
Crossref
Kelly A. Macedo, Peter Tatarian & Kenneth R. Eugenio. (2017) Influence of Direct Oral Anticoagulants on Anti–Factor Xa Measurements Utilized for Monitoring Heparin. Annals of Pharmacotherapy 52:2, pages 154-159.
Crossref
Crossref
Jonathan M. Yaghoubian, Jacob Adashek, Bahareh Yaghoubian-Yazi, Menachem Nagar, Nojan Toomari, Richard J. Pietras & Uri M. Ben-Zur. (2017) Incomplete Resolution of Deep Vein Thromboses during Rivaroxaban Therapy. Case Reports in Cardiology 2017, pages 1-6.
Crossref
Crossref